Navigation Links
ChromaDex Names Pharmaceutical Industry Veteran William F. Spengler as President
Date:10/28/2010

s that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to: the ability to market, produce and sell the referenced ingredients; risks relating to product and customer demand, market acceptance of our products; the effect of economic conditions both nationally and internationally; the ability to protect our intellectual property rights; the impact of any litigation or infringement actions brought against us; competition from other providers and products; risks in product development; our ability to raise capital to fund continuing operations; the ability to complete transactions; and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.Investor InquiriesLiviakis Financial Communications, Inc.John M. Liviakis, President415-389-4670John@Liviakis.comChromaDex Contact Jenny RoblesAdministrative Assistant to the CEO10005 Muirlands Blvd, Suite G, Irvine, CA 92618949-419-0288jennyr@chromadex.comMedia ContactMegan LavineCanale Communications3033 5th Ave., Suite 400, San Diego, CA 92103619-849-5388megan@canalecomm.com
'/>"/>
SOURCE ChromaDex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ChromaDex Commences a Clinical Trial on pTeroPure™ Pterostilbene
2. ChromaDex Launches pTeroPure Pterostilbene
3. ChromaDex Announces 2008 Year End Financial Results
4. ChromaDex Announces Second Quarter 2008 Financial Results
5. WaferGen Names Gary P. Schroth, Ph.D., as New SVP, Genomics Research and Applications
6. Castle Access Names New Managing Director
7. Regenicin Names Former U.S. Marine Corp Operations Officer, Christopher Hadsall, Chief Operating Officer
8. Vaccinogen Names Veteran Biotech Executive Michael Kranda President & CEO
9. RF Technologies® Names Mark Harwood New President
10. FierceBiotech Names iPierian as One of the Fierce 15 Biotech Companies of 2010
11. DNASequencing.com and a Portfolio of 318 Genetic Domain Names to be Auctioned Off at Epik.com Domain Development Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015 The fully automated supercritical ... can sequentially analyze up to 48 samples utilizing ... detection of targets by mass spectrometry. , ... the measurement requirements of a wide range of ... delivery and search for disease biomarkers, additives in ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Cytokinetics, Incorporated ... on February 28 with patients and health care advocates ... for Rare Disease Day®. Rare Disease Day is ... calling attention to the special challenges faced by patients ... , “Cytokinetics is proud to stand alongside patients and ...
(Date:2/26/2015)... N.J. , Feb. 26, 2015 On ... and its affiliated companies, Wilentz, Goldman & Spitzer, ... trade secrets lawsuit against Genewiz Inc. in excess of ... and utilized GenScript,s trade secrets, and that it improperly ... entered an order denying motions for judgment notwithstanding the ...
(Date:2/26/2015)... Calif. , Feb. 26, 2015   Regulus ... biopharmaceutical company leading the discovery and development of innovative ... Xanthopoulos , Ph.D., President and Chief Executive Officer of ... and Company 35 th Annual Healthcare Conference on ... conference is being held at the Boston Marriott Copley ...
Breaking Biology Technology:Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3
... 11, 2011 Pacira Pharmaceuticals, Inc. ... new data highlighting the pain control and pharmacokinetic ... the company,s lead investigational product for postsurgical pain ... the 2011 Annual Meetings of the American Society ...
... N.Y., Oct. 10, 2011 The Leukemia & ... Apple Co-Founder Steve Jobs from pancreatic cancer. Jobs, death comes ... disease - those of Nobel Laureate Ralph Steinman last week, ... http://photos.prnewswire.com/prnh/20110215/NY48642LOGO ) These deaths bring to light ...
... AWAC, an inVentiv Health company, and a leading provider ... solutions, announced today that it has changed its name ... name and organization – unveiled today at the Self-Insurance ... better reflects the company,s expanded solutions, revitalized mission and ...
Cached Biology Technology:Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings 2Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings 3Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings 4Steve Jobs' Death Highlights Critical Need for New Therapies for Pancreatic Cancer 2AWAC Becomes inVentiv Medical Management™ 2
(Date:2/11/2015)... 11, 2015 According ... Control Market by Product (Cards and Readers, Biometrics, Controllers, ... Government, Industrial, Healthcare, Education) and By Geography - Global Forecast and ... the Access Control Market is expected to ... a CAGR of 10.6% between 2014 and ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America ... methods for carbon nanotube (CNT) macrostructures, including sheets, yarns ... Dallas (UTD). Leveraging the vast industrial resources ... Tokyo, Japan , Lintec of America is forming ... Richardson, TX , focusing on scaling up the ...
(Date:2/5/2015)... 2015  Marken is starting its 35 th ... a new marketing campaign to solidify its place as ... campaign focuses on First as a primary ... The first headline in the series, ... its client,s priorities. Marken recognizes the need to protect ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marken Launches New Patient-Centric Campaign 2
... diseases can rival malaria,s ability to kill and cripple. Each year ... and more than a million mostly African children under the ... anniversary of the announcement of the genome sequence of the deadly ... Anopheles . A new book on malaria ...
... shelves until Oct. 2, it has already passed an enviable ... 100 books of all time. And they fit on ... of Genetics at Harvard Medical School and a founding core ... Harvard University, and his team encoded the book, Regenesis: How ...
... as carbon drains but are far from places where greenhouses ... has proposed human, agricultural and livestock waste, such as urine, ... large quantities of carbon dioxide and other greenhouse gases present ... occurring substance. A study published in the Journal of ...
Cached Biology News:New book tells story of 10-year-old malaria project 2New book tells story of 10-year-old malaria project 3Writing the book in DNA 2Writing the book in DNA 3A urine based 'potion' can act as a CO2 absorbent 2A urine based 'potion' can act as a CO2 absorbent 3
Mouse monoclonal [4C4] to Y14 ( Abpromise for all tested applications). entrezGeneID: 9939 SwissProtID: Q9Y5S9...
...
Agarose, Biotechnology grade, 500g...
Clarin Mounting Medium (Permanent environmentally safe mounting medium for general histology & cytology use)...
Biology Products: